{"title":"与患有替诺福韦/恩曲他滨或卡波特韦耐药艾滋病毒的男性发生性传播感染的男性。","authors":"Tommaso Clemente, Michele Bellomo, Angelo Roberto Raccagni, Riccardo Lolatto, Sara Diotallevi, Rebecka Papaioannu Borjesson, Chiara Maci, Marcella Negri, Golnaz Torkjazi, Emanuela Messina, Simona Bossolasco, Antonella Castagna, Silvia Nozza, Vincenzo Spagnuolo","doi":"10.1097/QAD.0000000000004225","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Sexually transmitted infections (STIs) are associated with an increased risk of HIV transmission, raising concerns in case of virus resistant (R) to the drugs currently approved for preexposure prophylaxis. We explored the incidence of STIs in MSM with HIV (MSMWH) and resistance to tenofovir/emtricitabine (TXF/FTC) and/or cabotegravir (CAB).</p><p><strong>Design: </strong>Retrospective, cohort study on MSMWH on antiretroviral treatment (ART) with at least one genotyping resistance test (GRT) including integrase.</p><p><strong>Methods: </strong>The following STIs were included in the analysis: Neisseria gonorrhoeae , Chlamydia trachomatis , Mycoplasma/Ureaplasma spp. (only if symptomatic), early syphilis (primary, secondary, or early latent), and mpox infections. Poisson regression modeled incidence rates (IRs) and 95% confidence intervals (95% CIs).</p><p><strong>Results: </strong>Overall, 638 MSMWH evaluated: 67 (10.5%) TXF/FTC-R, 4 (0.6%) CAB-R, and 13 (2%) TXF/FTC+CAB-R. During a median follow-up of 9.6 (7.3-11.7) years [5908 person-years of follow-up (PY)], 307 of 638 (48.1%) individuals developed 744 STIs: IR = 12.6 (95% CI = 11.7-13.5)/100 PY. Among 307 MSMWH who developed STIs, 34 (11.1%) had at least one STI at HIV load at least 200 copies/ml [21 (6.8%) ≥1000 copies/ml]. Thirty-two (10.4%) of 307 individuals with at least one incident STI had TXF/FTC-R and/or CAB-R strains; five (15.6%) of these developed STIs at HIV load at least 200 copies/ml (specifically, ≥1000 copies/ml). STI incidence was significantly lower in presence of drug resistance [either TXF/FTC-R or CAB-R: IR = 8.2 (95% CI = 6.2-10.5)/100 PY and incidence rate ratio (IRR) = 0.6 (95% CI = 0.5-0.8); TXF/FTC+CAB-R: IR = 2.9 (95% CI = 0.8-7.3)/100 PY and IRR = 0.2 (95% CI = 0.1-0.5)].</p><p><strong>Conclusion: </strong>In our cohort of MSMWH, STI incidence was nonnegligible, although reduced, in presence of resistance to TXF/FTC and/or CAB. Discussion of HIV resistance test results should include the risk of sexual transmission uncontrolled by preexposure prophylaxis.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1397-1402"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sexually transmitted infections in MSM with tenofovir/emtricitabine-resistant or cabotegravir-resistant HIV.\",\"authors\":\"Tommaso Clemente, Michele Bellomo, Angelo Roberto Raccagni, Riccardo Lolatto, Sara Diotallevi, Rebecka Papaioannu Borjesson, Chiara Maci, Marcella Negri, Golnaz Torkjazi, Emanuela Messina, Simona Bossolasco, Antonella Castagna, Silvia Nozza, Vincenzo Spagnuolo\",\"doi\":\"10.1097/QAD.0000000000004225\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Sexually transmitted infections (STIs) are associated with an increased risk of HIV transmission, raising concerns in case of virus resistant (R) to the drugs currently approved for preexposure prophylaxis. We explored the incidence of STIs in MSM with HIV (MSMWH) and resistance to tenofovir/emtricitabine (TXF/FTC) and/or cabotegravir (CAB).</p><p><strong>Design: </strong>Retrospective, cohort study on MSMWH on antiretroviral treatment (ART) with at least one genotyping resistance test (GRT) including integrase.</p><p><strong>Methods: </strong>The following STIs were included in the analysis: Neisseria gonorrhoeae , Chlamydia trachomatis , Mycoplasma/Ureaplasma spp. (only if symptomatic), early syphilis (primary, secondary, or early latent), and mpox infections. Poisson regression modeled incidence rates (IRs) and 95% confidence intervals (95% CIs).</p><p><strong>Results: </strong>Overall, 638 MSMWH evaluated: 67 (10.5%) TXF/FTC-R, 4 (0.6%) CAB-R, and 13 (2%) TXF/FTC+CAB-R. During a median follow-up of 9.6 (7.3-11.7) years [5908 person-years of follow-up (PY)], 307 of 638 (48.1%) individuals developed 744 STIs: IR = 12.6 (95% CI = 11.7-13.5)/100 PY. Among 307 MSMWH who developed STIs, 34 (11.1%) had at least one STI at HIV load at least 200 copies/ml [21 (6.8%) ≥1000 copies/ml]. Thirty-two (10.4%) of 307 individuals with at least one incident STI had TXF/FTC-R and/or CAB-R strains; five (15.6%) of these developed STIs at HIV load at least 200 copies/ml (specifically, ≥1000 copies/ml). STI incidence was significantly lower in presence of drug resistance [either TXF/FTC-R or CAB-R: IR = 8.2 (95% CI = 6.2-10.5)/100 PY and incidence rate ratio (IRR) = 0.6 (95% CI = 0.5-0.8); TXF/FTC+CAB-R: IR = 2.9 (95% CI = 0.8-7.3)/100 PY and IRR = 0.2 (95% CI = 0.1-0.5)].</p><p><strong>Conclusion: </strong>In our cohort of MSMWH, STI incidence was nonnegligible, although reduced, in presence of resistance to TXF/FTC and/or CAB. Discussion of HIV resistance test results should include the risk of sexual transmission uncontrolled by preexposure prophylaxis.</p>\",\"PeriodicalId\":7502,\"journal\":{\"name\":\"AIDS\",\"volume\":\" \",\"pages\":\"1397-1402\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAD.0000000000004225\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004225","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Sexually transmitted infections in MSM with tenofovir/emtricitabine-resistant or cabotegravir-resistant HIV.
Objective: Sexually transmitted infections (STIs) are associated with an increased risk of HIV transmission, raising concerns in case of virus resistant (R) to the drugs currently approved for preexposure prophylaxis. We explored the incidence of STIs in MSM with HIV (MSMWH) and resistance to tenofovir/emtricitabine (TXF/FTC) and/or cabotegravir (CAB).
Design: Retrospective, cohort study on MSMWH on antiretroviral treatment (ART) with at least one genotyping resistance test (GRT) including integrase.
Methods: The following STIs were included in the analysis: Neisseria gonorrhoeae , Chlamydia trachomatis , Mycoplasma/Ureaplasma spp. (only if symptomatic), early syphilis (primary, secondary, or early latent), and mpox infections. Poisson regression modeled incidence rates (IRs) and 95% confidence intervals (95% CIs).
Results: Overall, 638 MSMWH evaluated: 67 (10.5%) TXF/FTC-R, 4 (0.6%) CAB-R, and 13 (2%) TXF/FTC+CAB-R. During a median follow-up of 9.6 (7.3-11.7) years [5908 person-years of follow-up (PY)], 307 of 638 (48.1%) individuals developed 744 STIs: IR = 12.6 (95% CI = 11.7-13.5)/100 PY. Among 307 MSMWH who developed STIs, 34 (11.1%) had at least one STI at HIV load at least 200 copies/ml [21 (6.8%) ≥1000 copies/ml]. Thirty-two (10.4%) of 307 individuals with at least one incident STI had TXF/FTC-R and/or CAB-R strains; five (15.6%) of these developed STIs at HIV load at least 200 copies/ml (specifically, ≥1000 copies/ml). STI incidence was significantly lower in presence of drug resistance [either TXF/FTC-R or CAB-R: IR = 8.2 (95% CI = 6.2-10.5)/100 PY and incidence rate ratio (IRR) = 0.6 (95% CI = 0.5-0.8); TXF/FTC+CAB-R: IR = 2.9 (95% CI = 0.8-7.3)/100 PY and IRR = 0.2 (95% CI = 0.1-0.5)].
Conclusion: In our cohort of MSMWH, STI incidence was nonnegligible, although reduced, in presence of resistance to TXF/FTC and/or CAB. Discussion of HIV resistance test results should include the risk of sexual transmission uncontrolled by preexposure prophylaxis.
期刊介绍：
Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
